Home・Aktien・Roivant Sciences Ltd

Roivant Sciences Ltd

Geschlossen

BrancheGesundheitswesen

34.94 1.04

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

33.93

Max

35.35

Schlüsselkennzahlen
By Trading Economics
Einkommen	669M 356M
Verkäufe	521K 2.5M
Gewinnspanne	14,116.825
Angestellte	721
EBITDA	744M 455M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+14.36% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	3.9B 24B
Vorheriger Eröffnungskurs	33.9
Vorheriger Schlusskurs	34.94

Nachrichtenstimmung

By Acuity

50%

156 / 340 Ranking in Healthcare

Roivant Sciences Ltd Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Roivant Sciences Ltd Prognose

Kursziel

By TipRanks

14.36% Vorteil

12-Monats-Prognose

Durchschnitt 39.57 USD 14.36%

Hoch 50 USD

Tief 34 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Roivant Sciences Ltd – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

7 ratings

Buy

Halten

Sell

Basierend auf 7 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Roivant Sciences Ltd – Dist abgegeben haben.

Stimmung

By Acuity

156 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.